Company: SION
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0002036042-25-000047
Chunk: 305

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 305
---
,370,621)(110,791)(18,628,970)(181,328)27,149,20627 330,340 — — 330,367 Issuance of common stock from initial public offering, net of issuance costs of $4,265—— —— —— —— 12,176,46712 199,558 — — 199,570 Vesting of restricted common stock awards—— —— —— —— 43,681— — — — — Stock-based compensation expense—— —— —— —— —— 2,094 — — 2,094 Unrealized loss on marketable securities—— —— —— —— —— — (67)— (67)Net loss—— —— —— —— —— — — (16,482)(16,482)Balance at March 31, 2025—$— —$— —$— —$— 44,092,117$44 $548,992 $301 $(197,568)$351,769 Exercise of common stock options————————7,944—6——6 Vesting of restricted common stock awards————————32,277————— Stock-based compensation expense——————————2,840——2,840 Unrealized loss on marketable securities———————————(118)—(118)Net loss————————————(18,068)(18,068)Balance at June 30, 2025—$— —$— —$— —$— 44,132,338$44 $551,838 $183 $(215,636)$336,429 

The accompanying notes are an integral part of these condensed consolidated financial statements. 

F-5

SIONNA THERAPEUTICS, INC. 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 

(in thousands) 

(Unaudited)Six Months EndedJune 30,20252024Cash flows from operating activities:Net loss$(34,550)$(20,399)Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense4,934 1,618 Non-cash operating lease expense981 982 Amortization of discount on marketable securities(1,863)(1,214)Depreciation expense306 332 Changes in operating assets and